FDA grants accelerated approval to Bristol Myers Squibb’s ZENBEXUS for relapsed multiple myeloma combo use

• FDA granted accelerated approval to Bristol Myers Squibb’s ZENBEXUS (iberdomide) with daratumumab and hyaluronidase-fihj, dexamethasone for relapsed multiple myeloma.
• Use covers adults with at least one prior line, including a proteasome inhibitor and an immunomodulatory agent.
• Clearance was based on MRD-negative complete response rate of 41% with ZDd vs 21% with DVd in EXCALIBER-RRMM.
• Full approval depends on confirmatory trials; mezigdomide NDA remains under FDA review with a May 13, 2027 target date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811027471) on August 13, 2026, and is solely responsible for the information contained therein.